Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06498284 · ClinicalTrials.gov registry record · Phase 1
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus
A Phase 1 study of Diabetes Mellitus Type II, sponsored by Hua Medicine Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06498284 is a Phase 1 study of Diabetes Mellitus Type II that has completed, run by Hua Medicine Limited. The registered enrollment target is 40 participants, below the 235-participant average among 7 other Diabetes Mellitus Type II trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06498284, a Phase 1 study of Diabetes Mellitus Type II, has completed, sponsored by Hua Medicine Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of this study are to: * Evaluate the safety and tolerability of the study drug. * Measure how much of the study drug (HM-002-1005) and its breakdown product get into the bloodstream, and how long it takes the body to get rid of them. * Measure the amount of glucose (blood sugar) and a substance called C-peptide in the bloodstream after receiving the study drug. Researchers will compare the study drug to a placebo (a look-alike substance that contains no drug). Participants will: * Stay 5 days and 4 nights or 6 days and 5 nights at the research site, and have a follow-up phone call 7 days after leaving the research site. * Take one (1) dose of the study drug or placebo * Have blood taken to measure the amount of study drug and its breakdown product and the levels of glucose and C-peptide * Have safety tests such as vital sign, ECGs, and glucose measurements
Conditions Studied
Interventions
- DRUG HM-002-1005
Study Locations (1)
Florida
- Clinical Pharmacology of Miami - Hialeah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-04-25 |
| Est. Completion | 2024-09-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06498284
The ClinicalTrials.gov registry entry for NCT06498284 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 235-participant average among 7 other Diabetes Mellitus Type II trials with a reported enrollment target (83% lower). The listed sponsor is Hua Medicine Limited, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus Type II appearing as the primary indexed condition, and to 1 intervention - of which HM-002-1005 is the first listed.
NCT06498284 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06498284 about?
NCT06498284 is a clinical study titled "Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus". The purposes of this study are to: * Evaluate the safety and tolerability of the study drug. * Measure how much of the study drug (HM-002-1005) and its breakdown product get into the bloodstream, and how long it takes the body to get rid of them. * Measure the amount of glucose (blood sugar) and a ...
What is the current status of trial NCT06498284?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-04-25. Estimated completion is 2024-09-06.
What conditions does trial NCT06498284 study?
This clinical trial studies the following conditions: Diabetes Mellitus Type II.
What interventions are being tested in trial NCT06498284?
The interventions under investigation include: HM-002-1005 (DRUG).
Who is sponsoring clinical trial NCT06498284?
This trial is sponsored by Hua Medicine Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06498284 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus Type II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery
RECRUITING · NA
-
Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana
ACTIVE NOT RECRUITING
-
Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics
COMPLETED · Phase 4
-
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
COMPLETED · Phase 2
-
GOLO Open-Label Pilot 1
COMPLETED · NA
-
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.